Navigation Links
Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Date:9/26/2007

ual sales of approximately $800 million in the US alone."

About Gentamicin Surgical Implant

GENTAMICIN SURGICAL IMPLANT is a fully biodegradable, leave-behind surgical implant impregnated with the broad spectrum aminoglycoside antibiotic, gentamicin. It was developed using Innocoll's proprietary collagen-based technology, CollaRx(R), and is designed to provide a high concentration of gentamicin (which has a concentration-dependent mechanism of action) at the target tissue while maintaining low systemic levels well below the toxicity threshold. The product is indicated as an adjunct to systemic antibiotic therapy for the prevention of surgical site infections and for the treatment of deep, localized infections in both hard and soft tissues. There are more than 60 prospective clinical trials and published case reports totalling over 7,500 patients documenting safety and efficacy over a broad range of orthopaedic, colorectal, cardiothoracic, vascular, and neurosurgical procedures. The product is already approved in 49 countries spanning Europe, Latin America, Middle East, Africa and Asia and is marketed by EUSA Pharma under the following trade names; COLLATAMP(R) G, COLLATAMP(R) EG, SULMYCIN(R) IMPLANT, GARAMYCIN(R) SCHWAMM, DURACOL(R), DURACOLL(R), GENTACOL(R), GENTACOLL(R), GARACOL(R), GARACOLL(R) and CRONOCOL(R).

GENTAMICIN SURGICAL IMPLANT is under development in the US for the prevention of surgical site infections. An IND has been approved by the FDA and Innocoll plans to conduct two US multi-centered phase 3 clinical trials; one in cardiac surgery patients at higher risk of surgical site infection and the other in patients undergoing open colorectal surgery. Innocoll has appointed Duke University's Duke Clinical Research Institute (DCRI) as the Study Co-ordinating Center for both trials. Independent market research recently performed by L.E.K. Consulting projected peak US sales of greater than US$200 million per annum.

About CollaRx(R) Ge
'/>"/>

SOURCE Innocoll, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...lif., Nov. 20 Bionovo, I...present results from the Phase 1B,clinical trial ...ic breast,cancer, BZL101, at the Society for Inte... in Atlanta, Georgia. The Company,s oral presenta...ill be presented as a part of the Best of the,SIO...
(Date:11/20/2008)...rway, November 20 The Scandinavian...as announced results of studies on its,lead antim...Washington, DC,the studies showed that the novel...cidal effect, significantly better towards killing... than marketed gold standard drugs. In,addition t...
(Date:11/19/2008)...N.Y., Nov. 19 Biotech scientists i...toxicology research to better understand the effec...systems, reports Genetic Engineering & Biotec...ted in figuring out a new compound,s mechanism of ...cology technique, according to the November 15 iss...
(Date:11/18/2008)...Nov. 18 Arlington Medical Resource...e for the pharmaceutical and diagnostic,imaging i...ing,s Privigen was,sold in the U.S. during the th... of intravenous immune globulin (IVIG) and was lau...duct created from the blood plasma of thousands,o...
Breaking Medicine Technology:Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 2Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 3Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 4Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology 5Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2GEN Reports on the Trend Toward Predictive Toxicogenomics 2Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2CryoCath to present at Piper Jaffray and BMO Healthcare conferences 6960 1CryoCath to present at Piper Jaffray and BMO Healthcare conferences 6960 2Environmental Tectonics Corporations Sterilization Systems Group Announces New Contracts 6957 1Environmental Tectonics Corporations Sterilization Systems Group Announces New Contracts 6957 2Environmental Tectonics Corporations Sterilization Systems Group Announces New Contracts 6957 3Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals 6955 1Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals 6955 2Sosei Announces Update on Phase I Trials for SD118 6953 1Sosei Announces Update on Phase I Trials for SD118 6953 2Sosei Announces Update on Phase I Trials for SD118 6953 3
(Date:11/21/2008)...abor , , FRIDAY, Nov. 21 (HealthDay News... activates the uterine muscles for contraction dur...es for preterm labor. , The molecule prostacyc...f these uterine muscle cells, keeping them relativ...rs from Dartmouth Medical School in New Hampshire,...
(Date:11/21/2008)...anuary 8, 2009 , , TORONTO, Nov. 21 /PRNews...edEmerg") (OTCBB: MDER), one of Canada,s leading p...it has obtained an interim order from the Ontario ...y announced plan of arrangement (the "Arrangement"...will acquire all of MedEmerg,s outstanding shares....
(Date:11/21/2008)...Health Science Center at Houston will launch a new...XAS), to promote geriatrics training for physician...Donald W. Reynolds Foundation and $1.25 million in...riatric medicine principles to everyone from the m...s. With the reach of Lyndon B. Johnson General Hos...
(Date:11/21/2008)... -- Heska Corporation,(Nasdaq: HSKA ) today ann...,Security Analysts, 12th Annual Biotech and Specia... Avenue of the Americas, 2nd Floor in New York, NY...a.m. Eastern Time (7:35 a.m.,Mountain Time) and w...s,following the presentation through a link under...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4
... Hospital doctors warn that children playing footb... from blisters caused by football boots // . Acco... toxic shock syndrome in the UK have been attribut...in children. However if misdiagnosed or left untre...
...ch is already running in a loss would have to pay ...s they are not in a position // to fulfil the comm...tem for the health services. The trusts in the so...d 50 full-time employees to help develop the ?20bn...
...radesh has decided to take action against erring P...has now fixed the number of patients //to be treat...y health centres so as to stop the 'popular' pract...eave the hospital early, at least an hour before t...
...as announced at the Cheltenham Science Festival th... mount Everest to conduct //a research into the ef...cientists from the Centre for Aviation, Space and ...nstitute of Human Health and Performance, Universi...
Other Medicine News:Health News:Budding Footballers at Risk from Blood Infection 2Health News:Already Short Staffed And In Deficit NHS Fails To Supply Staff For IT Project 2Health News:UP Government Fixes Work Schedules for Provincial Medical Service Doctors 2Health News:Mount Everest to be Site of Research into Hypoxia 2
Since 1991 Intersurgical Incorporated manufactures high efficiency breathing filters, heat and moisture exchangers, ventilator circuits, oxygen therapy products, hand-held nebulizers and an extensive
...The Ulti-Mist™ HME product line has the righ...to adults and from intubated patients to patients ...humidification for both anesthesia and critical ca...ers provide maximum protection for patients and st...
...These hygroscopic condenser humidifiers (HCH) capt...turn them in the inspired gas. Small and compact, ...ic and hygroscopic benefits. Depending on the tida...small-volume model., ,The adult HCH is ideal for ...
...These hygroscopic condenser humidifiers (HCH) capt...turn them in the inspired gas. Small and compact, ...ic and hygroscopic benefits. Depending on the tida...small-volume model., ,The adult HCH is ideal for ...
Medicine Products: